Dymista in Chinese Adolescents
← catalyst calendarNCT07597473 · readout ≤ 224 d
Sponsored by Viatris Inc. (industry) · VTRS — their whole pipeline →. With MEDA Pharma GmbH & Co. KG.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
15
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-08 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Allergic Rhinitis Due to Allergens
Intervention
- Drug: Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate
Primary outcome
what the primary-completion date above is the date OFChange from baseline in AM+PM combined reflective Total Nasal Symptom Score (rTNSS).
measured From enrollment to end of treatment at 2 weeks.
Permalink · VTRS's whole pipeline · Catalyst calendar · Every registered study · What changed